Patient characteristics for PS 341 + thalidomide phase 2 trial for advanced and refractory myeloma
Parameter . | % of patients . |
|---|---|
| Age 60 y or older | 61 |
| B2M 4 mg/L or greater | 61 |
| LDH 190 IU/L or greater | 43 |
| Abnormal cytogenetics | 76 |
| Deletion 13 | 52 |
| Prior therapy 60 mo or more | 37 |
| Prior autotransplantation | 100 |
| More than 1 cycle | 72 |
| Prior THAL | 78 |
| Prior VEL | 0 |
Parameter . | % of patients . |
|---|---|
| Age 60 y or older | 61 |
| B2M 4 mg/L or greater | 61 |
| LDH 190 IU/L or greater | 43 |
| Abnormal cytogenetics | 76 |
| Deletion 13 | 52 |
| Prior therapy 60 mo or more | 37 |
| Prior autotransplantation | 100 |
| More than 1 cycle | 72 |
| Prior THAL | 78 |
| Prior VEL | 0 |
All patients had relapsed from a prior autotransplantation; 78% had been treated with and were resistant to thalidomide (THAL); none had received prior PS 341 (VEL). Cytogenetic abnormalities were present in 76%, including deletion 13 in 52%.